Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin versus placebo for kidney senescence and inflammation markers in chronic kidney disease
2020-004835-26Phase 2Completed
- Sponsor
- IRCCS-A.O.U. SAN MARTINO-IST
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic kidney disease (CKD) comparing Dapagliflozin with Placebo (2 arms). Started Aug 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2020-004835-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004835-26.